RAF1 FUSION

Clinical trials for RAF1 FUSION explained in plain language.

Never miss a new study

Get alerted when new RAF1 FUSION trials appear

Sign up with your email to follow new studies for RAF1 FUSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Targeted drug trial for Tough-to-Treat cancers halted

Disease control Terminated

This study tested an experimental drug called DAY101 (tovorafenib) in people aged 12 and older with advanced solid tumors that had stopped responding to other treatments. The goal was to see if the drug could shrink or control tumors that have specific genetic changes. The trial …

Matched conditions: RAF1 FUSION

Phase: PHASE2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control

Last updated Mar 18, 2026 14:41 UTC

RAF1 FUSION

Get alerted when new RAF1 FUSION trials appear

Targeted drug trial for Tough-to-Treat cancers halted